Displaying drugs 2851 - 2875 of 4292 in total
MIV-701
MIV-701 is a selective, potent inhibitor of the protease Cathepsin K. It is developed for the treatment of osteoporosis.
Investigational
ABT-751
ABT-751 has been investigated for the treatment of Lung Cancer, Non-Small Cell Lung Cancer, and Non-Small-Cell Lung Cancer.
Investigational
GTX-758
GTX-758 is under investigation in clinical trial NCT01420861 (GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer).
Investigational
PRI-724
PRI-724 is under investigation in clinical trial NCT03620474 (Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis).
Investigational
CDX-1135
CDX-1135, formerly TP-10, is a soluble, recombinant human Complement Receptor Type 1 (sCR1) developed by Avant Immunotherapeutics (now Celldex). It was investigated in clinical trials for post-cardiopulmonary bypass syndrome and kidney damage.
Investigational
Matched Description: … CDX-1135, formerly TP-10, is a soluble, recombinant human Complement Receptor Type 1 (sCR1) developed …
L-Octahydroindole-2-carboxylic acid
Experimental
Tricarbonyl(1,10-phenanthroline)rhenium(1+)
Experimental
Naringenin
Experimental
Carbomer homopolymer type C
Carbomer homopolymer type C is a high molecular polyanionic substance tested for antiulcerogenic activity.
Experimental
Investigational
Matched Products: … LIPOTEARS %0,2 OFTALMİK JEL,10 GR …
Fresolimumab
Fresolimumab has been used in trials studying the treatment of Primary Brain Tumors, Metastatic Breast Cancer, Diffuse Systemic Sclerosis, Pleural Malignant Mesothelioma, and Primary Focal Segmental Glomerulosclerosis.
Investigational
SGS-742
SGS-742 has been used in trials studying the treatment of Seizures and Metabolic Disease.
Investigational
RTA 744
RTA 744 is a novel anthracycline derivative that crosses the blood-brain barrier and shows significant potential for the treatment of primary and metastatic brain cancers. Anthracyclines are one of the most broadly used and effective classes of cancer therapies; however, they are not used to treat brain cancers because current...
Investigational
AT-7519
AT7519 is a selective inhibitor of certain Cyclin Dependent Kinases (CDKs) leading to tumour regression. It is developed by Astex for the treatment of solid tumours and haematological malignancies.
Investigational
MK-7145
MK-7145 has been used in trials studying the treatment of Hypertension and Renal Insufficiency.
Investigational
AEE-788
AEE788 has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Brain and Central Nervous System Tumors.
Investigational
ABP-700
ABP-700 is under investigation in clinical trial NCT02800590 (Study to Investigate the Safety and Efficacy of 3 Dosing Regimens of ABP-700 for Procedural Sedation in Adult Participants Undergoing Colonoscopy).
Investigational
STP-707
STP-707 is a small interfering RNA (siRNA) targeting TGF-Beta1 and COX-2 mRNA.
Investigational
Allylestrenol
A synthetic steroid with progestational activity. It is widely marketed throughout Europe, including Russia and many other European countries, and is also available in Japan, Hong Kong, India, Bangladesh, Indonesia, and much of Southeast Asia, though notably not in the United States or Canada.
Experimental
HY10275
HY10275 is a novel compound specifically designed to modulate two key neurobiological mechanisms that interfere with the sleeping process. HY10275 is highly selective for histamine H1 and serotonin 5HT2a, two chemical receptors that are known to impact the ability to fall asleep and stay asleep. HY10275 was rationally designed to...
Investigational
CMLVAX100
CMLVAX100 is a vaccine targeting the BCR-ABL-derived p210 fusion protein which reduces residual disease in some patients with chronic myeloid leukemia. It is developed by Breakthrough Therapeutics and has completed phase I of its clinical trial.
Investigational
MIP-1095 I-123
123 I Mip 1095 is under investigation in clinical trial NCT00712829 (Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents).
Investigational
ANG1005
Investigational
CT103A
CT103A is an investigational BCMA-targeted genetically modified autologous T-cell immunotherapy.
Investigational
Displaying drugs 2851 - 2875 of 4292 in total